Compare · CVII vs IBER
CVII vs IBER
Side-by-side comparison of Churchill Capital Corp VII (CVII) and Ibere Pharmaceuticals (IBER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVII and IBER operate in Blank Checks (Finance), so they compete in similar markets.
- CVII is the larger of the two at $1.68B, about 10.0x IBER ($167.2M).
Churchill Capital Corp VII
Churchill Capital Corp VII focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Ibere Pharmaceuticals
Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Latest CVII
- Amendment: SEC Form SC 13G/A filed by Churchill Capital Corp VII
- SEC Form 15-12G filed by Churchill Capital Corp VII
- Large owner Magnetar Financial Llc disposed of $90,084,438 worth of shares (8,306,005 units at $10.85) (SEC Form 4)
- Churchill Capital Corp VII filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Churchill Capital Corp VII
- Churchill Capital Corp VII and CorpAcq Mutually Agree to Terminate Business Combination
- SEC Form 10-Q filed by Churchill Capital Corp VII
- Churchill Capital Corp VII filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Churchill Capital Corp VII
- SEC Form DEFA14A filed by Churchill Capital Corp VII
Latest IBER
- SEC Form 15-12G filed by Ibere Pharmaceuticals
- SEC Form 25-NSE filed by Ibere Pharmaceuticals
- Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form 10-Q filed by Ibere Pharmaceuticals